The Blue Shield of California has considered Xdx's AlloMap Molecular Expression Testing to monitor heart transplant rejections.
AlloMap Molecular Expression Testing is a non-invasive gene expression test which aids physicians to identify the probability of acute cellular rejection for post-cardiac transplant patient management.
The AlloMap also identifies heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment.
AlloMap testing measures the expression levels of 20 genes from a blood sample and the combined expression of these genes is represented as an AlloMap test score.
Xdx president and CEO Pierre Cassigneul said they are pleased with Blue Shield of California’s favorable coverage decision, providing them with the opportunity to impact the quality of life for stable patients by reducing the number of invasive biopsies performed post-transplantation.